GAITHERSBURG, Md., Jan. 5 /PRNewswire/ -- Emergent BioSolutions Inc. announced today that it will participate in the 24th Annual JP Morgan Healthcare Conference, January 9-12, in San Francisco. Chairman and Chief Executive Officer Fuad El-Hibri will speak to attendees of the conference on Tuesday, January 10th at 10:30 a.m. PST/1:30 p.m. EST. His discussion will provide a company overview and outline future growth opportunities for the company.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is dedicated to the research, development, and manufacture of immunobiotics(TM), which are novel products which harness the immune system to prevent and treat disease. These include products for prophylactic and therapeutic use against common infectious diseases and against biological weapons. The company currently employs more than 400 people with facilities in Gaithersburg and Frederick, Maryland, Lansing, Michigan, Berkshire, UK, and Munich, Germany. More information about Emergent BioSolutions and its subsidiaries can be found at http://www.ebsi.com .
Emergent BioSolutions Inc.
CONTACT: Kim Brennen Root of Emergent BioSolutions Inc., +1-517-327-1543,rootk@bioport.com
Web site: http://www.ebsi.com/
